Drug class

Genetic Disorder Therapy - SMN Protein Deficiency Treatment

The phrase "Genetic Disorder Therapy - SMN Protein Deficiency Treatment" functions primarily as an administrative formulary and compendial classification rather than a formal pharmacologic drug class. Read more about Genetic Disorder Therapy - SMN Protein Deficiency Treatment

2 drugs in this class 2 manufacturers

Advertisement

Drugs in Genetic Disorder Therapy - SMN Protein Deficiency Treatment

Showing 1–2 of 2 drugs

EVRYSDI (risdiplam)

GENETIC DISORDER THERAPY - SMN PROTEIN DEFICIENCY TREATMENT · SPINAL MUSCULAR ATROPHY
GENENTECH
Filter & compare in the drug finder → Opens the drug finder with Genetic Disorder Therapy - SMN Protein Deficiency Treatment preselected. Add indication or manufacturer filters there.

About Genetic Disorder Therapy - SMN Protein Deficiency Treatment.

The phrase "Genetic Disorder Therapy - SMN Protein Deficiency Treatment" functions primarily as an administrative formulary and compendial classification rather than a formal pharmacologic drug class.

This category encompasses disease-modifying agents designed to treat spinal muscular atrophy (SMA), an autosomal recessive neuromuscular disorder marked by the loss of spinal motor neurons due to survival motor neuron (SMN) protein deficiency.

Therapies within this grouping, such as risdiplam and nusinersen, work by enhancing functional SMN protein production through modifying SMN2 pre-messenger RNA splicing, whereas associated gene replacement therapies directly supply functional SMN1 coding sequences.

Clinically, these agents improve motor function, halt disease progression, and increase survival in pediatric and adult patients with spinal muscular atrophy.